Clinical trials in Hoofddorp – page 12

1 940 clinical trials in Hoofddorp, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Hoofddorp at a glance

1 940

clinical trials

Research sites1

Quick filters

1 940 trials in Hoofddorp

Open in trial search

Amyotrophic lateral sclerosis

Recruiting

Safety and Tolerability of Intrathecal TRCN-1023 in Adults with Amyotrophic Lateral Sclerosis (ALS) – Randomized Placebo‑Controlled Phase 1/2 Trial

Investigational

Safety and Tolerability of Intrathecal TRCN-1023 in Adults with Amyotrophic Lateral Sclerosis (ALS) – Randomized Placebo‑Controlled Phase 1/2 Trial

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:TRCN-1023
Sponsor:Trace Neuroscience Inc.

Contact Research Centre

Pancreatitis

Recruiting

Tacrolimus for prevention of post-ERCP pancreatitis in moderate- to high-risk patients

Registered drug

Tacrolimus for prevention of post-ERCP pancreatitis in moderate- to high-risk patients

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Tacrolimus
Sponsor:Amsterdam UMC Stichting

Contact Research Centre

Duchenne muscular dystrophy+1

Recruiting

Long‑Term Safety and Efficacy Study of ENTR‑601‑45 and ENTR‑601‑44 in Participants with Duchenne Muscular Dystrophy

InvestigationalNo placebo

Long‑Term Safety and Efficacy Study of ENTR‑601‑45 and ENTR‑601‑44 in Participants with Duchenne Muscular Dystrophy

InvestigationalNo placebo

The Netherlands

Participants:0–17 years · 18–64 years
Substances:ENTR-601-44
Sponsor:Entrada Therapeutics Inc.

Contact Research Centre

Prostate cancer metastatic

Recruiting

Phase I/II Study of AZD6621 Safety and Efficacy in Adult Men with Metastatic Prostate Cancer

InvestigationalNo placebo

Phase I/II Study of AZD6621 Safety and Efficacy in Adult Men with Metastatic Prostate Cancer

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:AZD6621
Sponsor:AstraZeneca AB

Contact Research Centre

Gastric cancer+1

Recruiting

Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

Registered drugNo placebo

Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:AZD0901
Sponsor:AstraZeneca AB

Contact Research Centre

Polymyalgia rheumatica

Recruiting

Efficacy and safety of sarilumab plus prednisone versus prednisone alone in adults with early polymyalgia rheumatica

Registered drug

Efficacy and safety of sarilumab plus prednisone versus prednisone alone in adults with early polymyalgia rheumatica

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Prednisone
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

B-cell type acute leukaemia

Recruiting

Study of MK-1045 versus blinatumomab with tocilizumab in patients with relapsed or refractory B-cell acute lymphoblastic leukemia

Registered drugNo placebo

Study of MK-1045 versus blinatumomab with tocilizumab in patients with relapsed or refractory B-cell acute lymphoblastic leukemia

Registered drugNo placebo

The Netherlands

Participants:0–17 years · 18–64 years · 65+ years
Substances:Blinatumomab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

Registered drug

Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Durvalumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Venetoclax added to fludarabine, cytarabine and gemtuzumab ozogamicin (drug combination) in children with relapsed acute myeloid leukemia

Registered drugNo placebo

Venetoclax added to fludarabine, cytarabine and gemtuzumab ozogamicin (drug combination) in children with relapsed acute myeloid leukemia

Registered drugNo placebo

The Netherlands

Participants:0–17 years · 18–64 years
Substances:Azacitidine
Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Contact Research Centre

Rheumatoid arthritis

Recruiting

Discontinuation of methotrexate (drug combination) in rheumatoid arthritis patients using TNF inhibitors

Registered drugNo placebo

Discontinuation of methotrexate (drug combination) in rheumatoid arthritis patients using TNF inhibitors

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Adalimumab
Sponsor:Sint Maartenskliniek

Contact Research Centre

Malignant mast cell neoplasm

Recruiting

Phase 1/2 Study of VS-7375 with Drug Combination in Patients with Advanced KRAS G12D‑Mutated Solid Tumors

Registered drugNo placebo

Phase 1/2 Study of VS-7375 with Drug Combination in Patients with Advanced KRAS G12D‑Mutated Solid Tumors

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Verastem Inc.

Contact Research Centre

Chronic lymphocytic leukaemia+2

Recruiting

Rituximab and venetoclax treatment for 6 vs 26 cycles in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo

Rituximab and venetoclax treatment for 6 vs 26 cycles in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Venetoclax
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Hoofddorp

What the registry says about research in the country

01 Oncology Research

Extensive research focusing on various cancer types including breast cancer, bladder cancer, and melanoma. Studies are evaluating novel treatment combinations and maintenance therapies for improved patient outcomes.

Advanced/Metastatic Breast Cancer Treatments
Urothelial Cancer Therapies
Hematologic Malignancies

Multiple trials are investigating innovative approaches for both solid tumors and blood cancers, with particular emphasis on targeted therapies.

02 Hematologic Disorders

Comprehensive studies examining treatments for various blood disorders, including chronic myeloid leukemia, myelofibrosis, and lymphomas. Focus on developing targeted therapies and combination treatments.

B-Cell Lymphoma Treatments
Myelofibrosis Therapies
Leukemia Management

Research aims to improve treatment outcomes and quality of life for patients with blood disorders.

03 Metabolic and Surgical Studies

Research initiatives addressing obesity management and surgical conditions like appendicitis. Studies include weight management therapies and surgical technique improvements.

Weight Management Interventions
Surgical Techniques
Prevention Studies

Trials focus on both therapeutic and surgical interventions for better patient outcomes.

Back to the Netherlands All countries